An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide

Environmental and Molecular Mutagenesis

Volumn 49, Issue 2, 2008, Pages 117-131

  McCarroll, Nancy ^a   Keshava, Nagalakshmi ^b   Cimino, Michael ^a   Chu, Margaret ^a   Dearfield, Kerry ^c   Keshava, Channa ^b   Kligerman, Andrew ^d   Owen, Russell ^a   Protzel, Alberto ^a   Putzrath, Resha ^a   Schoeny, Rita ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cyclophosphamide; Cytotoxicity; Mode of action; Mutagenicity

Indexed keywords

ACROLEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; PHOSPHORAMIDE MUSTARD;

ACUTE NONLYMPHOCYTIC LEUKEMIA; BLADDER CANCER; BLADDER TUMOR; BREAST CANCER; CANCER MODEL; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONFERENCE PAPER; CYTOTOXICITY; DATA ANALYSIS; DNA DAMAGE; DRUG METABOLISM; GENETIC ANALYSIS; GENOTOXICITY; HAMSTER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MUTAGENICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OCCUPATIONAL EXPOSURE; OVARY CANCER; PEDIATRICS; PRELEUKEMIA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SISTER CHROMATID EXCHANGE; TREATMENT DURATION;

ANIMALS; CARCINOGENS; CYCLOPHOSPHAMIDE; GUIDELINES AS TOPIC; HUMANS; MUTAGENICITY TESTS; MUTAGENS; NEOPLASMS; RISK ASSESSMENT;

ANIMALIA; CRICETINAE; MUS; RATTUS;

EID: 40149103979     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20372     Document Type: Conference Paper

References (52)

1. Ammenheuser MM, Ward JB, Whorton EB, Killian JM, Legator MS. 1988. Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: A prospective study. Mutat Res 204:509-520.
2. Anderson D, Bishop JB, Gardner RC, Ostrosky-Wegman P, Selby PB. 1995. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 330:115-181.
3. Ashby J, Hilton J, Dearman RJ, Callander RD, Kimber I. 1993. Mechanistic relationship among mutagenicity, skin sensitization, and skin carcinogenicity. Environ Health Perspect 101:62-67.
4. Benson AJ, Martin CN, Gardner RC. 1988. N-(2-hydroxyethyl)-N-(7-guaninyl)ethyl] amine, the putative major DNA adduct of cyclophosphamide in vitro and in vivo in the rat. Biochem Pharm 37:2979-2985.
5. Bochkov NP, Filippova TV, Kuzin SM, Stukalova SV. 1986. Cytogenetic effects of cyclophosphamide on human lymphocytes in vivo and in vitro. Mutat Res 159:103-107.
6. Braun R, Hüttner E, Schöneich J. 1986. Transplacental genetic and cytogenetic effects of alkylating agents in the mouse. II. Induction of chromosome aberrations. Terat Carcinog Mutagen 6:69-80.
7. Burgaz S, Karahalil B, Bayrak P, Taskin L, Yavuzaslan F, Bokesoy I, Anzion RB, Bos RP, Platin N. 1999. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated epithelial cells of nurses handling antineoplastics. Mutat Res 439:97-104.
8. Butterworth B. 2006. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens. Regul Toxicol Pharmacol 45:9-23.
9. Campobasso O, Berrino F. 1972. Early effects of cyclophosphamide on mouse bladder epithelium. Pathol Microbiol 38:144-157.
10. Clare MG, Jones WG, Taylor JH. 1982. Sister chromatid exchanges in human lymphocytes exposed to single cytotoxic drugs in vivo or in vitro. Eur J Cancer Clin Oncol 18:979-989.
11. Cohen SM, Garland EM, St. John M, Okamura T, Smith RA. 1992. Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res 52:3577-3581.
12. Cox PJ. 1979. Cyclophosphamide cystitis - Identification of acrolein as the causative agent. Biochem Pharmacol 28:2045-2049.
13. Dearfield KL, Moore MM. 2005. Use of genetic toxicology information for risk assessment. Environ Mol Mutagen 46:236-245.
14. Dearfield KL, Jacobson-Kram D, Buenaventura SK, Williams JR. 1985. In vitro assays of in vivo exposure to cyclophosphamide: Induction of sister-chromatid exchanges in peripheral lymphocytes, bone marrow cells and in cultured cells exposed to plasma. Mutat Res 158:97-104.
15. Dearfield KL, Stack HF, Quest JA, Whiting RJ, Waters MD. 1993. A survey of EPA/OPP and open literature data on selected pesticide chemicals tested for mutagenicity. I. Introduction and first 10 chemicals. Mutat Res 297:197-233.
16. Dobos M, Schuler D, Fekete G. 1974. Cyclophosphamide-induced chromosomal aberrations in non tumorous patients. Humangenetik 22:221-227.
17. Fritsche M, Haessler C, Brandner G. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318.
18. Goetz P, Sram RJ, Dohnalova J. 1975. Relationship between experimental results in mammals and man. I. Cytogenetic analysis of bone marrow injury induced by a single dose of cyclophosphamide. Mutat Res 31:247-254.
19. Gorelick NJ, Andrews JL, deBoer JG, Young R, Gibson DP, Walker VE. 1999. Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice. Environ Mol Mutagen 34:154-166.
20. Hass JF, Kittleman B, Mehnert WH, Staneczek W, Mohner M, Kaldor JM, Day NE. 1987. Risk of leukaemia in ovarian tumor and breast cancer patients following treatment by cyclophosphamide. Br J Cancer 55:213-218.
21. Heimlich B, Kausch I, Doehn C, Jocham D, Holl-Ulrich K, Gross WL. 2004. Urinary bladder cancer in Wegener's granulomatosis: Is it more than cyclophosphamide? Ann Rheum Dis 63:1183-1185.
22. Hemminki K. 1985. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Cancer Res 45:4237-4243.
23. IARC. 1981. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some Antineoplastic and Immunosuppressive Agents, Cyclophosphamide, Vol 26. Lyon, France:International Agency for Research on Cancer. pp 165-185.
24. IARC. 1998. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some Antineoplastic and Immunosuppressive Agents, Cyclophosphamide, Suppl 7. Lyon, France: International Agency for Research on Cancer. pp 182-184.
25. Jung I, Messing E. 2000. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 7:325-334.
26. Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, Holowaty EJ, van Leeuwen FE, Glimelius B, Stovall M, Boice JD, Tarone RE, Bennett WP. 1998. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 7:397-403.
27. King M-T, Wild D. 1979. Transplacental mutagenesis: The micronucleus test on fetal mouse blood. Hum Genet 51:183-194.
28. Kitchell BE. 2005. Practical chemotherapy - An overview. Proceedings of the 30th World Congress of the World Small Animal Veterinary Association, Mexico City, Mexico, May 11-14, 2005. Available at: http://www.vin.com/proceedings/ Proceedings.plx?CID=WSAVA2005&PID=Generic.
29. Koss LG. 1967. A light and electron microscopic study of the effects of a single dose of cyclophosphamide on various organs in the rat. I. The urinary bladder. Lab Invest 16:44-65.
30. Krishna G, Kropko ML, Ciaravino V, Theiss JC. 1991. Simultaneous micronucleus and chromosome aberration assessment in the rat. Mutat Res 264:29-35.
31. Lambert IB, Singer TM, Boucher SE, Douglas GR. 2005. Detailed review of transgenic rodent mutation assays. Mutat Res 590:1-280.
32. Lohman WJA, Lohman PHM. 2000. Genetic activity profiles of short-term testing data from the US EPA and from the IARC monographs. GAP2000 version 1.3 for Windows, 2000.
33. McCarroll NE, Protzel A, Ioannou Y, Stack HF, Jackson MA, Waters MD, Dearfield KL. 2002. A survey of EPA/OPP and open literature on selected pesticide chemicals. III. Mutagenicity and carcinogenicity of benomyl and carbendazim. Mutat Res 512:1-35.
34. McEvoy GK, editor. 2002. American Hospital Formulary Service - Drug Information 2002 (Plus Supplements). Bethesda, MD: American Society of Health-System Pharmacist, Inc. pp 960-961.
35. Musilova J, Michalova K, Urban J. 1979. Sister-chromatid exchanges and chromosomal breakage in patients treated with cytostatics. Mutat Res 67:289-294.
36. Myhr BC. 1991. Validation studies with Muta™ mouse: A transgenic mouse model for detecting mutations in vivo. Environ Mol Mutagen 18:308-315.
37. Phillips FS, Sternberg SS, Cronin AP, Vidal PM. 1961. Cyclophosphamide and urinary bladder toxicity. Cancer Res 21:1577-1589.
38. Povirk LF, Shuker DE. 1994. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 318:205-226.
39. Schmähl D, Habs M. 1979. Carcinogenic action of low-dose cyclophosphamide given orally to Sprague-Dawley rats in a lifetime experiment. Int J Cancer 23:706-712.
40. Schuler D, Dobos M, Fekete G, Kiltenyi M, Kalmar L. 1979. Chromosome mutations and chromosome stability in children treated with different regimes of immunosuppressive drugs. Hum Hered 29:100-105.
41. Sessink JM, Kroese ED, van Kranen HJ, Bos RP. 1995. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 67:317-323.
42. Simula AP, Priestly BG. 1992. Species differences in the genotoxicity of cyclophosphamide and styrene in three in vivo assays. Mutat Res 271:49-58.
43. Tennant RW. 1993. Stratification of rodent carcinogenicity bioassay results to reflect relative human hazard. Mutat Res 286:111-118.
44. Toxnet SIS. 2003. Acrolein. Report published by the National Library of Medicine, Specialized Information Services. Available at: http://toxnet.nlm.nih. gov/cgi-bin/sis/search/f?./temp/~wioBV7:18:BODY.
45. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, Gospodarowicz MK, Wacholder S, Inskip PD, Tucker MA, Boice Jr JD. 1995. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl Cancer Inst 87:524-530.
46. Tsuda S, Matsusaka N, Madarame H, Miyamae Y, Ishida K, Satoh M, Sekihashi K, Sasaki YF. 2000. The alkaline single cell electrophoresis assay with eight mouse organs: results with 22 monofunctional alkylating agents (including 9 dialkyl N-nitrosamines) and 10 DNA crosslinkers. Mutat Res 467:83-98.
47. USEPA. 2005a. Guidelines for Carcinogenic Risk Assessments, EPA/630/P-03/001F, March 2005. Available at: http://www.epa.gov/cancer guidelines.
48. USEPA. 2005b. Supplemental Guidance for Assessing Cancer Susceptibility from Early-Life Exposure to Carcinogens, EPA/630/R-03/003F, March 2005. Available at: http://www.epa.gov/cancer guidelines.
49. Vaghef H, Nygren P, Edling C, Bergh J, Hellman B. 1997. Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: A pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide. Mutat Res 395:127-138.
50. Walker VE, Andrews JL, Upton PB, Skopek TR, deBoer JG, Walker DM, Shi X, Sussman HE, Gorelick NJ. 1999. Detection of cyclophosphamide-induced mutations at the Hprt but not the lacI locus in splenic lymphocytes of exposed mice. Environ Mol Mutagen 34:167-181.
51. Waters MD, Stack HF, Brady AL, Lohman PHM, Haroun I, Vainio H. 1988. Use of computerized data listings and activity profiles of genetic and related effects in the review of 195 compounds. Mutat Res 205:295-312.
52. WHO. 1991. World Health Organization Environmental Health Criteria for Acrolein. Environmental Health Criteria Document Number 127. Available at: http://www.inchem.org.